GlassScriptPhysician profile
Kenneth M Mcdowell
NPI 1306834379
$14,882.07
in general payments reported to CMS, 2019-2025
64 companies · $1,973 in 2025
The $1,973 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,033 · 2020: $1,572 · 2021: $2,285 · 2022: $2,523 · 2023: $2,359 · 2024: $2,137 · 2025: $1,973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,438 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,437.59 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,505.52 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,365.70 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,210.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $963.49 | 2019-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $957.12 | 2019-2025 | Rexulti, Nuedexta |
| Lilly USA, LLC | $947.75 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $895.25 | 2019-2025 | |
| Amgen INC. | $696.94 | 2019-2025 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $502.47 | 2019-2025 | |
| Glaxosmithkline, LLC. | $482.36 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lundbeck LLC | $431.22 | 2020-2025 | Rexulti, Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $431.13 | 2019-2025 | Trintellix |
| Allergan, INC. | $421.66 | 2019-2020 | |
| Astellas Pharma US INC | $342.18 | 2019-2025 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $338.03 | 2020-2024 | Nexletol |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Mcdowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.